Management is prioritizing speed to market by removing COVID-19 from its initial upper respiratory multiplex submission due to a lack of positive samples across eight U.S. study locations.

The company is transitioning its CoSara joint venture in India toward a self-sustaining public entity, exploring a potential SPAC transaction to fund its capital requirements.

Strategic expansion in South Asia has increased the addressable market to approximately $13 billion by adding Bangladesh, Pakistan, Nepal, and Sri Lanka to CoSara's territory.

The CoMira joint venture is positioning to be the first domestic manufacturer of molecular diagnostics in Saudi Arabia, leveraging local procurement preferences for a competitive advantage.

Operational readiness in India is being accelerated by the CDSCO license to manufacture the PCR Pro instrument locally, supported by an established oligonucleotide lab.

The company is aligning its TB diagnostic platform with new WHO guidelines that recommend near point-of-care molecular tests and non-invasive tongue swab sampling.

A new AI business unit, Co-Dx primer, is being launched to integrate machine learning into assay design, result interpretation, and predictive outbreak modeling.

Management expects to achieve commercialization of the tuberculosis (TB) test in India by the third quarter of 2026, following clinical trials in the region.

The upper respiratory submission for Flu A, Flu B, and RSV is being fast-tracked, with the flexibility to add COVID-19 back once epidemiological trends provide sufficient clinical samples.

Financial sustainability depends on a mix of equity, debt, and strategic partnerships, alongside an active ATM facility to manage liquidity during the pre-revenue phase.

The company anticipates continued operating losses in the near term as it funds clinical submissions and the build-out of manufacturing facilities in Saudi Arabia.

Future growth assumes the successful technology transfer of PCR Pro manufacturing from Utah to international joint ventures to achieve scalable, local production.

A non-cash impairment charge of approximately $18.9 million related to in-process R&D intangible assets significantly impacted the 2025 net loss.

Revenue declined to $0.6 million from $3.9 million primarily due to the expiration of previously awarded grant funding recognized in 2024.

The company successfully appealed a NASDAQ delisting, resolving a temporary disruption to its listing status during the reporting period.

Cash and marketable securities decreased to $11.9 million at year-end 2025, down from $29.7 million in the prior year, reflecting ongoing platform investment.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management clarified that removing COVID-19 was a pragmatic decision to avoid a protracted trial, as the virus 'just simply did not show up' at clinical sites.

Re-adding the target will not require a chemistry redesign or re-engineering, but will involve a future negotiation with the FDA regarding required sample sizes.

The company remains adaptable and can 'light up' the COVID-19 component once sufficient positive samples become available in the environment.

The expansion into neighboring countries like Pakistan and Bangladesh is driven by a similar disease burden to India and a desire to maximize the mature CoSara infrastructure.

This move increases the total addressable market by $2 billion and leverages existing manufacturing and sales teams already operating on the subcontinent.

The U.S. clinical trial is nearing conclusion with over 1,200 patients already enrolled across multiple sites.

The company is currently preparing for analytical studies and final submission to the FDA for the three-target respiratory panel.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.